Schizophrenia,schizophreniform and schizoaffective disorder Clozapine, psychotic disorders
Conditions
Interventions
None
Sponsors
University Medical Center Utrecht
Eligibility
Inclusion criteria
Inclusion criteria: -he/she is about to initiate CLZ (i.e. he/she has an indication to start CLZ treatment according to the treating physician and he/she is willing to start on CLZ) -he/she has received a diagnosis of schizophrenia, schizophreniform disorder, schizoaffective disorder or psychosis not otherwise specified. -his/her age must be ≥18 years old -he/she must be able to speak and read the Dutch language -he/she must be mentally competent with regard to a decision to participate in the current study
Exclusion criteria
Exclusion criteria: - admission to a psychiatric unit involuntarily in the context of an ‘inbewaringstelling’ (IBS) - a history of Parkinson’s disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reponse and the development of ADRs after clozapine intake. We think this is influenced by methylation patterns and gene expression | — |
Secondary
| Measure | Time frame |
|---|---|
| We measure non-genetic factors such as smoking, cannabis use, duration of illness etc., because we think these influence treatment outcome (ADRs+response) as well. In addition, we use the data with our other protocol (NTR 5257) to create a prediction model for clozapine response and side effects. | — |
Contacts
Public ContactMarte van der Horst
UMCU A01.126
Outcome results
None listed